Ponatinib dials down the hyperactive signalling pathway of the enzyme MEKK3 associated with mutations in cerebral cavernous malformation (CCM) genes. The pre-clinical research opens up the potential for a treatment to prevent CCM initiation or progression and reduce the risk of sequelae such as stroke and neurological deficits. The limbic asked Dr Xiangjian Zheng, head ...
Already a member?
Enter your email to keep reading.